Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice

Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice

The therapeutic sc"enario of metastatic renal cell cancer (mRCC) has noticeably increased, ranging from the most studied molecular target therapies to those most recently introduced, up to immune checkpoint inhibitors (ICIs). The most recent clinical trials with an ICI-based combination of mole...

Full description

Bibliographic Details
Main Authors: Michela Roberto, Andrea Botticelli, Martina Panebianco, Anna Maria Aschelter, Alain Gelibter, Chiara Ciccarese, Mauro Minelli, Marianna Nuti, Daniele Santini, Andrea Laghi, Silverio Tomao, Paolo Marchetti
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
renal cancer carcinoma
targeted therapy
tyrosine kinase inhibitor (TKI)
immune checkpoints inhibitor
new biomarkers
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.657639/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.657639/full

Similar Items